A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

SUPPLEMENTARY MATERIALS Reverse phase protein array (RPPA)
RPPA was carried out as previously described by us [10, 18] . Protein extraction lysates were normalized to 1.5 μg/μL concentration as assessed by bicinchoninic acid assay (DC Protein Assay -Bio-Rad, CA, USA). 3 parts of cell lysates were mixed with 1 part of an SDS buffer (40% Glycerol, 8% SDS, 0.25M Tris-HCL, pH 6.8 plus 2-mercaptoehtanol at 1/10 of the volume) and boiled. Lysates were manually diluted in four-fold serial dilutions with lysis buffer.
A 2470 Arrayer (Aushon BioSystem, MA, USA), created a sample array on Oncyte Avid nitrocellulosecoated slides (Grace Bio-Labs, OR, USA). The slides were stored with desiccant (Drierite, OH, USA) at −20 °C prior to immunostaining.
Immunostaining was performed on an automated slide stainer (Dako Link 48 -Dako, CA, USA) according to the manufacturer's instructions (CSA kit -Dako, CA, USA). Each slide was incubated with a single primary antibody (see Table 1 for details) at room temperature for 30 min. Secondary antibody was goat anti-rabbit IgG (1:5000) (Vector Laboratories, CA, USA) or rabbit antimouse IgG (1:10) (Dako, CA, USA). Dako Secondary antibodies were used as a starting point for amplification via horseradish peroxidase-mediated biotinyl tyramide with chromogenic detection (diaminobenzidine) according to the manufacturer's instructions (Dako, CA, USA ).
Scanned TIFF images of slides were analyzed using Microvigene software version 5.1 (VigeneTech Inc., MA, USA) to generate spot signal intensities [44] . Instead of generating multiple linear regression curves for data quantification over each series of serial dilutions, the QRPPA module of Microvigene using a 4 parameter logistic-log model ("SuperCurve" algorithm [45] ) that uses all spots within one array to form a sigmoid antigen-binding kinetic curve.
Finally the spots are normalized by protein loading using the entire panel of antibodies. Briefly, normalization is processed as follows: we determined the median for each antibody across the sample set and we divided each raw linear value by the median within each antibody to get the median-centered ratio. After that, we calculated the median from median-centered ratio for each sample across the entire panel of antibodies. This median functions as a correction factor (CF) for protein loading adjustment. We considered the samples an outlier if the CF is above 2.5 or below 0.25. Finally, we divided the raw data in linear value by the CF to obtain the normalized value.
Calculation for fold change in protein expression phosphorylation
The formula to calculate fold change is calculated according to the error of propagation,
The formula to calculate the standard deviation according to the error of propagation is, 
